Synergy Asset Management LLC Purchases 2,085 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Synergy Asset Management LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 67.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,198 shares of the medical research company’s stock after purchasing an additional 2,085 shares during the period. Synergy Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $3,021,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of TMO. Allspring Global Investments Holdings LLC increased its position in shares of Thermo Fisher Scientific by 40.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 125,565 shares of the medical research company’s stock valued at $72,980,000 after buying an additional 36,169 shares during the period. Oak Thistle LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at $321,000. Park Place Capital Corp grew its holdings in shares of Thermo Fisher Scientific by 14.0% during the first quarter. Park Place Capital Corp now owns 2,530 shares of the medical research company’s stock valued at $1,470,000 after buying an additional 311 shares during the last quarter. Claro Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific during the first quarter valued at $345,000. Finally, Talbot Financial LLC increased its position in Thermo Fisher Scientific by 2.5% during the first quarter. Talbot Financial LLC now owns 15,481 shares of the medical research company’s stock valued at $8,998,000 after acquiring an additional 374 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research reports. The Goldman Sachs Group upped their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Deutsche Bank Aktiengesellschaft increased their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Barclays lowered their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a report on Friday. Jefferies Financial Group reiterated a “buy” rating and issued a $650.00 price objective (up from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Finally, HSBC increased their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $606.47.

Thermo Fisher Scientific Trading Down 1.1 %

Shares of TMO stock traded down $6.14 on Tuesday, hitting $535.58. 478,527 shares of the company’s stock traded hands, compared to its average volume of 1,542,543. The company’s fifty day simple moving average is $574.84 and its 200 day simple moving average is $563.36. The stock has a market capitalization of $204.44 billion, a price-to-earnings ratio of 34.53, a P/E/G ratio of 2.58 and a beta of 0.77. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend is Friday, June 14th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,873,516.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the sale, the senior vice president now owns 13,083 shares in the company, valued at $7,430,359.02. The disclosure for this sale can be found here. Insiders have sold 22,000 shares of company stock valued at $12,532,780 in the last quarter. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.